OVERVIEW
Dr. William Pao will present a patient advocacy webinar on the history of lung cancer treatments on Monday, November 2.

Dr. William Pao will discuss lung cancer drug development in the era of precision medicine. He will review how genomic testing, targeted therapies, immunotherapy, and acquired drug resistance are shaping the development of new drugs. Dr. Pao’s presentation will be followed by a Q and A session moderated by Janet Freeman-Daily. Target Audience: This presentation is part of the IASLC STARS (Supportive Training for Advocates on Research and Science) program for Patient Research Advocates and is open to anyone interested in these topics, or anyone whose life is impacted by lung cancer.

Faculty and Moderator Disclosures
William Pao, MD discloses he is an employee of Roche and has ownership/stock interest in Roche. The rights to EGFR T790M testing were licensed by MSKCC on his behalf and others.
Janet Freeman-Daily, MS, Eng discloses she receives travel expenses from STAT News and Turning Point Therapeutics and is on an advisory board for Genentech.

Planners and Reviewers Disclosures
Kristin Ito has no financial relationships to disclose.
Kirsten Black, PhD, MPH has no financial relationships to disclose.
Aubrey Shoe, MA has no financial relationships to disclose.

At the end of this activity learners will have:
gained knowledge about the history of precision medicine related to lung cancer
increased their confidence in discussing precision medicine with the lung cancer community